The Ayurvedic medicine ‘ViraNorm’ shows breakthrough results in the reduction of NL Ratio and increase of cellular immunity in the fight against Covid-19
Bengaluru: The Bengaluru-based Khoday Group of Industries has rolled out a first-of-its-kind Ayurvedic immuno-modulator ‘VIRANORM’ that helped Covid patients recover quickly in a recently concluded clinical trial. With ‘ViraNorm’, the Khoday Group is making its entry into the field of science-based alternative medicine.
‘ViraNorm’ approved by AYUSH has been developed by the Khoday Group in collaboration with Althea DRF Life Sciences. ‘ViraNorm’ has undergone one of the largest randomised multicentre phases 3 clinical trials in the country for an Ayurvedic formulation.
This trial was conducted in leading institutions like Victoria hospital, Bengaluru, and was carried out in line with international standards for clinical trials, said, Swamy Khoday, Vice Chairman and Managing Director of Khoday Group, in a press conference on Saturday.
Ayurvedic immuno-modulator ‘ViraNorm’ was developed post extensive safety and efficacy studies, and was found to be effective in the clinical trial” says Dr. Manu Jaggi COO, Althea DRF Lifesciences. ‘ViraNorm’ helps halt the progression of the virus in the body. ‘ViraNorm’ can therefore be referred to as an add-on therapy/medication for asymptomatic and mildly symptomatic COVID patients. ‘ViraNorm’ helps in stopping the migration of the patients from mild to moderate condition, explained Dr. K.G.Padmanabhan who has developed the formulation for this medicine.
Principal Investigator of the ‘ViraNorm’ clinical trial Dr. Radheshyam Naik said Neutrophil- Lymphocyte Ratio (NLR) has increasingly come under the spotlight as a very useful, rapid and inexpensive prognostic biomarker for Covid-19 patients, where elevated NLR levels may be associated with unfavorable clinical prognosis.
“In COVID-19 infections, low NLR levels (ratio factor between 0.75-3.00 is considered as normal) may indicate lower inflammation and higher Cytotoxic T cell immunity, and may signify lower COVID-19 viral loads, and may aid in better recovery,” said Dr. Radheshyam Naik.
The human body fights against diseases by showing two types of immunities. One is ‘antibody-mediated immunity, and the other is ‘cell-mediated immunity. The newly developed Ayurvedic medicine, ‘ViraNorm’ was proven to improve the patients’ cell-mediated immunity in the clinical trial, thereby helping patients to recover faster, he added.
Further, it was proven in the clinical trial, that, ‘ViraNorm’ also reduces both the duration and the severity of cough and breathlessness significantly, which are the primary symptoms of COVID patients. The ingredients in the capsule work by not letting the adhesion of the virus to the cell surface of the individual in nasal or oral cavity regions told Dr. Padmanbhan.
He further said the reduced NLR ensures reduction in Cellular Level Inflammation and increases Cell-Mediated Immunity. “This is the only alternative medicine that has been systematically proven to reduce NLR in a clinical trial. Since this is developed on the fundamental basis of immunity, it may work even for variants of the virus,” said Dr. Padmanbhan.
Further, it was proven in the clinical trial that ‘ViraNorm’ also reduces both the duration and the severity of cough and breathlessness significantly, which are the primary symptoms of COVID patients, pointed out Dr. Padmanbhan.
‘ViraNorm’ Key Points
• Made out of 100% natural herbal extracts
• Clinical Trial conducted in Victoria Hospital of Bengaluru on 250 patients
• AYUSH approved, As per CTRI guidelines
• Reduces Viral load by reducing N/L Ratio
• Reduces the severity of cough, duration and shortness of breath
• Effective both in <40 & > 60 age groups
Leading healthcare industry expert Rajeev Nagi said very interestingly, this promotion of T cell immunity and reduction of cellular inflammation seems to be in both younger (less than 40 years), as well as older (more than 60 years) patients.
“While older patients have always been a vulnerable age group, the ongoing 2nd wave of COVID-19 is also affecting younger patients in large numbers and therefore this observation seems important,” says Rajeev Nagi.
He further added the enhanced Cell Immunity plays its role in long-term recovery. ‘ViraNorm’ is also safe for patients suffering from co-morbidities such as hypertension and diabetes,” said Rajeev Nagi.
Swamy Khoday emphasised ‘ViraNorm’ made out of natural ingredients backed by scientific principles will assist in getting cured of ailments and maintain health without any adverse effect.
The Clinical Trial for ‘‘ViraNorm’ was done in Victoria Hospital and other institutions of Bengaluru, which are NABH (National Accreditation Board for Hospitals) accredited. The trial was done with the approval of CTRI (Clinical Trials Registry- India).
For this 250 Covid subjects were randomised and enrolled for the trial that lasted for 6 months. These 250 patients were divided into two arms of 125 each. One group was administered the ‘ViraNorm’ and the other was not. After a detailed analysis of the trial, it was found, that those who were administered ‘ViraNorm’ fared better compared to those who were not administered this medicine.
‘ViraNorm’ is available at LK Wellness Centre (#75, 3rd Cross, Residency Road, Bengaluru- 560025) and can be contacted on 080-40934216/ 93801 74977. ‘ViraNorm’ is priced at Rs 2000/- per bottle of 60 capsules.